Download PDF

1. Company Snapshot

1.a. Company Description

Aclaris Therapeutics, Inc.operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States.It operates through two segments: Therapeutics and Contract Research.


The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.The Contract Research segment engages in the provision of laboratory services.The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis.


In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer.The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Show Full description

1.b. Last Insights on ACRS

Aclaris Therapeutics' recent performance was driven by multiple catalysts in immuno-inflammatory indications expected in 2025 and 2026. The company received phase 2 results from its Chinese partner CTTQ, providing clinical evidence of enhanced potency of Bosakitug (ATI-045) and opportunities for development partnerships. Additionally, the Investigational New Drug (IND) application for bispecific antibody ATI-052 was cleared by the U.S. FDA. The company also extended its cash runway through the first half of 2028 and participated in several healthcare conferences, including the H.C. Wainwright Inflammation & Immunology Virtual Conference. These developments suggest a positive outlook for the company's future prospects.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov -25

Source: globenewswire.com

Card image cap

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates

Nov -06

Source: zacks.com

Card image cap

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov -06

Source: globenewswire.com

Card image cap

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Oct -29

Source: globenewswire.com

Card image cap

What Makes Aclaris Therapeutics (ACRS) a Strong Momentum Stock: Buy Now?

Oct -21

Source: zacks.com

Card image cap

Aclaris Therapeutics, Inc. - Special Call

Oct -14

Source: seekingalpha.com

Card image cap

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

Sep -30

Source: globenewswire.com

Card image cap

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aug -27

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (3.60%)

6. Segments

Therapeutics

Expected Growth: 3.5%

Aclaris Therapeutics' 3.5% growth in therapeutics is driven by increasing demand for innovative dermatology treatments, expanding product pipeline, and strategic partnerships. Growing prevalence of skin diseases, such as atopic dermatitis and psoriasis, also contribute to the growth. Additionally, the company's focus on developing novel therapies and expanding into new markets fuels the segment's growth.

Contract Research

Expected Growth: 4.5%

Aclaris Therapeutics' 4.5% growth in Contract Research is driven by increasing demand for outsourcing clinical trials, expansion into new therapeutic areas, and strategic partnerships. Additionally, the company's expertise in rare and orphan diseases, as well as its investments in digital technologies, have enhanced its competitiveness and attracted new clients.

7. Detailed Products

Eskata

A topical treatment for raised seborrheic keratoses (SKs), a common benign skin growth.

RHOFADE

A topical cream for the treatment of persistent facial erythema (redness) associated with rosacea.

A-101 40% Topical Solution

A topical solution for the treatment of seborrheic keratoses (SKs).

A-101 15% Topical Solution

A topical solution for the treatment of seborrheic keratoses (SKs).

8. Aclaris Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Aclaris Therapeutics, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for skin and hair conditions.

Bargaining Power Of Customers

Aclaris Therapeutics, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual customers.

Bargaining Power Of Suppliers

Aclaris Therapeutics, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials.

Threat Of New Entrants

Aclaris Therapeutics, Inc. has a high threat of new entrants due to the attractiveness of the dermatology and aesthetics markets.

Intensity Of Rivalry

Aclaris Therapeutics, Inc. operates in a highly competitive market with several established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 2.18%
Debt Cost 3.95%
Equity Weight 97.82%
Equity Cost 5.16%
WACC 5.13%
Leverage 2.23%

11. Quality Control: Aclaris Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Aclaris Therapeutics

A-Score: 4.7/10

Value: 6.8

Growth: 6.7

Quality: 4.0

Yield: 0.0

Momentum: 9.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
VolitionRx

A-Score: 4.1/10

Value: 8.0

Growth: 6.4

Quality: 6.1

Yield: 0.0

Momentum: 3.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Personalis

A-Score: 3.8/10

Value: 6.4

Growth: 3.1

Quality: 4.1

Yield: 0.0

Momentum: 8.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Inotiv

A-Score: 3.6/10

Value: 9.8

Growth: 3.2

Quality: 4.6

Yield: 0.0

Momentum: 3.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
T2 Biosystems

A-Score: 3.2/10

Value: 10.0

Growth: 4.7

Quality: 4.8

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Bionano Genomics

A-Score: 3.1/10

Value: 9.8

Growth: 4.3

Quality: 3.0

Yield: 0.0

Momentum: 0.5

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.01$

Current Price

3.01$

Potential

-0.00%

Expected Cash-Flows